Natera (NTRA) reported Q2 2026 revenue of ~$753M, up ~38% YoY, driven by record testing volumes and higher average selling prices across oncology, women’s health, and organ health. The strong top-line growth is a constructive fundamental signal for the business’s demand and pricing power.
Natera (NTRA) reported Q2 2026 revenue of ~$753M, up ~38% YoY, driven by record testing volumes and higher average selling prices across oncology, women’s health, and organ health. The strong top-line growth is a constructive fundamental signal for the business’s demand and pricing power.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
